T1	Participants 503 622	184 patients, and all received initial infusions of Z (so any first infusion reactions did not confound preferences for
T2	Participants 123 331	patients with common cancers involving bone receiving intravenous bisphosphonate therapy for either pamidronate (P) or zoledronic acid (Z) and their preference for the location of the infusion (clinic or home
